These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

345 related items for PubMed ID: 7649071

  • 1. [Antiparkinson drugs in neuroleptic treatment: comparative study of progressive and abrupt withdrawal].
    Ben Hadj Ali B, Dogui M, Ben Ammou S, Lôo H.
    Encephale; 1995; 21(3):209-15. PubMed ID: 7649071
    [Abstract] [Full Text] [Related]

  • 2. [Comparison of 6 different methods for lorazepam withdrawal. A controlled study, hydroxyzine versus placebo].
    Lemoine P, Touchon J, Billardon M.
    Encephale; 1997; 23(4):290-9. PubMed ID: 9417395
    [Abstract] [Full Text] [Related]

  • 3. No difference in the effect of biperiden and amantadine on parkinsonian- and tardive dyskinesia-type involuntary movements: a double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients.
    Silver H, Geraisy N, Schwartz M.
    J Clin Psychiatry; 1995 Apr; 56(4):167-70. PubMed ID: 7713856
    [Abstract] [Full Text] [Related]

  • 4. Withdrawal symptoms after long-term treatment with low-potency neuroleptics.
    Chouinard G, Bradwejn J, Annable L, Jones BD, Ross-Chouinard A.
    J Clin Psychiatry; 1984 Dec; 45(12):500-2. PubMed ID: 6150030
    [Abstract] [Full Text] [Related]

  • 5. Neuroleptic-induced acute extrapyramidal syndromes and tardive dyskinesia.
    Casey DE.
    Psychiatr Clin North Am; 1993 Sep; 16(3):589-610. PubMed ID: 8105453
    [Abstract] [Full Text] [Related]

  • 6. Antipsychotic medication: clinical guidelines for maintenance therapy.
    Johnson DA.
    J Clin Psychiatry; 1985 May; 46(5 Pt 2):6-15. PubMed ID: 2859281
    [Abstract] [Full Text] [Related]

  • 7. Ethopropazine and benztropine in neuroleptic-induced parkinsonism.
    Chouinard G, Annable L, Ross-Chouinard A, Kropsky ML.
    J Clin Psychiatry; 1979 Mar; 40(3):147-52. PubMed ID: 33969
    [Abstract] [Full Text] [Related]

  • 8. [Anticholinergics during neuroleptic treatment. Value and withdrawal].
    Betermiez P, Delahousse J, Pedinielli JL.
    Encephale; 1986 Mar; 12(4):169-74. PubMed ID: 2878801
    [Abstract] [Full Text] [Related]

  • 9. Neuroleptic withdrawal in patients meeting criteria for supersensitivity psychosis.
    Singh H, Hunt JI, Vitiello B, Simpson GM.
    J Clin Psychiatry; 1990 Aug; 51(8):319-21. PubMed ID: 1974249
    [Abstract] [Full Text] [Related]

  • 10. Depressive symptoms in chronic schizophrenic patients after withdrawal of long-acting neuroleptics.
    Wistedt B, Palmstierna T.
    J Clin Psychiatry; 1983 Oct; 44(10):369-71. PubMed ID: 6643398
    [Abstract] [Full Text] [Related]

  • 11. [The risk of neuroleptic discontinuation in schizophrenia].
    Jarema M.
    Psychiatr Pol; 1999 Oct; 33(1):69-81. PubMed ID: 10786216
    [Abstract] [Full Text] [Related]

  • 12. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study.
    Bai YM, Yu SC, Lin CC.
    J Clin Psychiatry; 2003 Nov; 64(11):1342-8. PubMed ID: 14658949
    [Abstract] [Full Text] [Related]

  • 13. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
    Midha KK, Hubbard JW, Marder SR, Marshall BD, Van Putten T.
    J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
    [Abstract] [Full Text] [Related]

  • 14. The initiation of long-term pharmacotherapy in schizophrenia: dosage and side effect comparisons between oral and depot fluphenazine.
    Schooler NR, Levine J.
    Pharmakopsychiatr Neuropsychopharmakol; 1976 Jul; 9(4):159-69. PubMed ID: 790413
    [Abstract] [Full Text] [Related]

  • 15. Molindone and haloperidol in tardive dyskinesia.
    Glazer WM, Hafez HM, Benarroche CL.
    J Clin Psychiatry; 1985 Aug; 46(8 Pt 2):4-7. PubMed ID: 2862139
    [Abstract] [Full Text] [Related]

  • 16. A double-blind controlled study of intramuscular zuclopenthixol acetate and liquid oral haloperidol in the treatment of schizophrenic patients with acute exacerbation.
    Chouinard G, Safadi G, Beauclair L.
    J Clin Psychopharmacol; 1994 Dec; 14(6):377-84. PubMed ID: 7884017
    [Abstract] [Full Text] [Related]

  • 17. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.
    Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, Labelle A, Beauclair L, Arnott W.
    J Clin Psychopharmacol; 1993 Feb; 13(1):25-40. PubMed ID: 7683702
    [Abstract] [Full Text] [Related]

  • 18. Clozapine treatment of psychosis in patients with tardive dystonia: report of three cases.
    Friedman JH.
    Mov Disord; 1994 May; 9(3):321-4. PubMed ID: 7913739
    [Abstract] [Full Text] [Related]

  • 19. The need for continuous use of antiparkinsonian medication with chronic schizophrenic patients receiving long-term neuroleptic therapy.
    Manos N, Gkiouzepas J, Logothetis J.
    Am J Psychiatry; 1981 Feb; 138(2):184-8. PubMed ID: 6109453
    [Abstract] [Full Text] [Related]

  • 20. [Complete neuroleptic withdrawal in patients with schizophrenia with intense symptoms and resistant to treatment].
    Wolf MA, Bailly L, Diener JM, Martinet JP, Peretti S, Garneau Y.
    Encephale; 1991 Feb; 17(4):255-61. PubMed ID: 1683626
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.